Table 3.

Patients With Myocardial Injury^a

No	Age (y)	Sex	Clinical Cardiac Diagnosis	LVEF Nadirb	Wall Motion Abnormality	Peak High-Sensitivity Troponin T (ng/L)c	Management, Events, Death Due to COVID-19
1	49	Male	Myocarditis	47%	Basal/mid	526	Venovenous ECMO
2	84	Male	Status post cardiac arrest, prior coronary artery bypass grafting, presumed ischemic cardiomyopathy	25%	Global	237	Torsades de pointes cardiac arrest, shock, RRT, death
3	53	Male	Myocarditis	31%	Basal/mid	76	Small pericardial effusion
4	61	Female	Myocarditis/stress cardiomyopathy	18%	Mid/apex	2367	Shock, RRT, pulmonary embolism
5	70	Male	Stress cardiomyopathy	40%	Mid/apex	28	Shock, left ventricular thrombus, deep venous thrombosis, RRT
6	75	Female	Stress cardiomyopathy	48% (−29%)	Global	47	Shock, RRT, moderate pericardial effusion, death
7	77	Female	Stress cardiomyopathy	50%	Mid/apex	47	Diabetic ketoacidosis
8	95	Female	NSTEMI	46% (−15%)	Inferior, inferoseptal	257	New atrial fibrillation, death
9	82	Female	NSTEMI	20%	Mid/apex	292	3-vessel percutaneous coronary intervention
10	70	Male	NSTEMI	65%	None	227	3-vessel coronary artery bypass graft
11	68	Female	NSTEMI	60%	None	163	Death
12	78	Male	NSTEMI	38%	Anterior, inferior, apex	2375	Shock, atrial fibrillation, right ventricular dysfunction, death
13	47	Male	NSTEMI	62%	None	105	Percutaneous coronary intervention

^aCOVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; LVEF, left ventricular ejection fraction; NSTEMI, non–ST-elevation myocardial infarction; RRT, renal replacement therapy.

^bIn parenthesis, change in left ventricular ejection fraction from most recent prior echocardiographic study.

^cReference: ≤15 ng/mL.